Clinical Trials Logo

Sickle Cell-beta-thalassemia clinical trials

View clinical trials related to Sickle Cell-beta-thalassemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03763656 Completed - Sickle Cell Disease Clinical Trials

Pharmacokinetics of Oral Hydroxyurea Solution

HUPK
Start date: November 20, 2018
Phase: Phase 2
Study type: Interventional

An open label, safety and pharmacokinetic study of oral hydroxyurea solution administered to children from 6 months to 17.99 years (i.e. to the day before 18th birthday), with a 12 to 15 month treatment period for each participant. The study treatment duration will be for 6 months at the maximum tolerated dose [MTD], which is usually reached by 6 months after initiation of treatment. For patients in whom time to MTD is longer than 6 months or not achieved at all, the maximum duration of study treatment will be 15 months.

NCT ID: NCT01966367 Active, not recruiting - Sickle Cell Disease Clinical Trials

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

Start date: March 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This study's goal is to determine the frequency and severity of acute graft versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, to determine the time to neutrophil and platelet engraftment, to determine the time to immune reconstitution (including normalization of T, B and natural killer (NK) cell repertoire and Immunoglobulin G production), and to establish the incidence of infectious complications including bacterial, viral, fungal and atypical mycobacterial and other infections following CD34+ selection in children, adolescents and young adults receiving an allogeneic peripheral blood stem cell transplant from a family member or unrelated adult donor for a non-malignant disease.